Pfizer Inc. (PFE) and Astellas Pharma Inc., Friday announced the positive results from the Phase 3 EV-304 clinical trial for PADCEV in combination with Keytruda in patients with muscle-invasive bladder cancer.
Before and after surgery data revealed a 47% reduction in the risk of tumor recurrence, progression or death compared to patients treated with standard of care neoadjuvant gemcitabine and cisplatin.
Additionally, an estimated 79.4% of patients were event-free at two years, relative to 66.2% treated with standard of care neoadjuvant chemotherapy.
Further, the study showed a 35% reduced risk of death in patients treated with perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant chemotherapy.
The EV-304 results, combined with the EV-303 study, provide compelling evidence that perioperative enfortumab vedotin plus pembrolizumab may offer survival benefits in the curative setting for patients with muscle-invasive bladder cancer, the company stated.
Currently, PFE is trading at $27.28, up 0.64 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.